SLDB (Solid Biosciences Inc.) Expected net earnings per share growth this year
Solid Biosciences Inc. (SLDB) is minimizing risks by developing comprehensive treatments for cardiac and neuromuscular pathologies. However, a high burn rate and uncertainty surrounding gene therapy trials pose threats to the business. A year-over-year EPS comparison demonstrates efficiency dynamics, where the parameter value equals 16.60, aligning with market expectations regarding R&D expenditures and the launch of new research phases.
Financial and market metric breakdowns for Solid Biosciences Inc. (SLDB)
- share price and consensus valuation forecast:
- business market valuation indicators:
- shareholders' equity book value data:
- debt and liquidity details:
Total Debt to Equity Ratio Solid Biosciences Inc.|SLDB - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient solidbio.com|SLDB - Company Aggregate Debts|Debts to Book Value Solid Corp|SLDB - Company Long-Term Debt|Company Short-Term Indebtedness Solid Biosciences|Quick Liquidity Indicator solidbio.com
- company profitability and valuation multiples indicators:
SLDB - Net Profit|Expected Net Profit Solid Biosciences Inc.|SLDB - Price to Earnings Ratio|Market Cap to Projected Earnings Solid Corp|SLDB - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Solid Corp|SLDB - Operating profit EBITDA|Net earnings per share for the last four quarters Solid Biosciences|SLDB - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months solidbio.com|SLDB - Earnings growth in current year|Expected earnings per share growth for next year Solid Biosciences Inc.
- revenue and sales proceeds data:
Fundamental valuation:SLDB Solid Biosciences Inc
Assessing the investment reliability of assets begins with an analysis of net earnings per share dynamics, which determines the efficiency of business capitalization. This EPS growth compared to the same period last year measures the annual percentage change in profit, which for the non-cyclical gene therapy sector of Solid Biosciences Inc. (SLDB) reflects clinical research progress and the company's operational resilience rather than market conditions.
Main competitors
TEM (Tempus Labs) - Earnings per share growth in current year|QGEN (Qiagen Group) - Earnings growth in current year|Isis Pharmaceuticals (IONS) - Expected net earnings per share growth this year|Earnings per share growth in current year Repligen Corporation (RGEN)|RNA - Earnings per share growth rate in current year|Earnings per share growth in current year CRISPR Therapeutics CRSP|Expected net earnings per share growth this year GeneDx Holdings (WGS)|Ultragenyx Pharma - Earnings growth in current year|Beam Tx (BEAM) - Net earnings per share growth this year|SRPT: Earnings growth in current year|TWST - Expected net earnings per share growth this year|TXG (10x Genomics) - Earnings growth in current year|Earnings per share growth rate in current year Intellia Therapeutics Inc NTLA|Earnings per share growth in current year Stoke (STOK)|BioLife - Earnings per share growth this year|Earnings growth in current year WVE (Wave Life Sciences)|MAZE - Net earnings per share growth this year|Sionna Therapeutics - Earnings growth in current year|Earnings per share growth rate in current year Prime Medicine Inc|Taysha (TSHA) - Earnings per share growth in current year|QURE - Expected net earnings per share growth this year|Net earnings per share growth this year MGTX|RGNX: Earnings per share increase in current year|Earnings growth in current year OCGN|Expected net earnings per share growth this year Pacific Biosciences of California, Inc.|Earnings per share growth in current year Benitec BNTC|DSGN: Earnings per share growth this year|Rocket Pharmaceuticals - Earnings growth in current year|4dmoleculartherapeutics.com (FDMT) - Net earnings per share growth this year|LXEO (lexeotx.com) - Net earnings per share growth this year|KRRO - Expected net earnings per share growth this year|Earnings per share growth in current year Editas|Silence Therapeutics Corp (SLN) - Expected net earnings per share growth this year|Earnings per share growth in current year ProQR Therapeutics N.V. (PRQR)|Earnings per share growth in current year CDXS (codexis.com)|Earnings growth in current year SGMO (Sangamo Therapeutics, Inc.)|NAUT: Earnings per share growth this year|Metagenomi, Inc - Earnings growth in current year|DTIL: Earnings per share growth in current year|GBIO: Earnings growth in current year|Earnings per share growth this year BOLD|Earnings per share growth in current year Exicure Inc.|Earnings per share growth this year IMNN (Celsion Corporation)|Earnings growth in current year PHIO|Earnings growth in current year mustangbio.com (MBIO)|Earnings per share growth in current year TransCode Therapeutics, Inc. RNAZ|Expected net earnings per share growth this year Bionano Genomics Inc. (BNGO)|APDN - Earnings per share growth in current year|Earnings per share growth rate in current year bluebird bio Inc.|immunoprecise.com (IPA) - Earnings per share growth in current year|OMGA (Omega Therapeutics Corp) - Earnings per share growth in current year|OMIC (Singular Genomics Systems) - Earnings growth in current year|regulusrx.com (RGLS) - Expected net earnings per share growth this year|Earnings growth in current year SYRS|Telesis Bio Inc. - Earnings per share growth this year|TRACON - Net earnings per share growth this year|Earnings per share increase in current year UBX
